|
KMID : 1200020230470050612
|
|
Diabetes & Metabolism Journal
2023 Volume.47 No. 5 p.612 ~ p.629
|
|
|
Dyslipidemia in Patients with Chronic Kidney Disease: An Updated Overview
|
|
Suh Sang-Heon
Kim Soo-Wan
|
|
|
Abstract
|
|
|
|
Dyslipidemia is a potentially modifiable cardiovascular risk factor. Whereas the recommendations for the treatment target of dyslipidemia in the general population are being more and more rigorous, the 2013 Kidney Disease: Improving Global Outcomes clinical practice guideline for lipid management in chronic kidney disease (CKD) presented a relatively conservative approach with respect to the indication of lipid lowering therapy and therapeutic monitoring among the patients with CKD. This may be largely attributed to the lack of high-quality evidence derived from CKD population, among whom the overall feature of dyslipidemia is considerably distinctive to that of general population. In this review article, we cover the characteristic features of dyslipidemia and impact of dyslipidemia on cardiovascular outcomes in patients with CKD. We also review the current evidence on lipid lowering therapy to modify the risk of cardiovascular events in this population. We finally discuss the association between dyslipidemia and CKD progression and the potential strategy to delay the progression of CKD in relation to lipid lowering therapy.
|
|
|
KEYWORD
|
|
|
Dyslipidemias, Kidney diseases, Risk
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|